Bactiguard has signed an exclusive co-operation with Cadila Pharmaceuticals, one of the largest healthcare manufacturing groups in India. A signing process took place at the Swedish Ambassadorâs residency.
Cadila Pharmaceuticals will sell the entire line of BactiguardÂ´s products throughout India. The Indian medical device market is currently worth approximately 2 billion US dollar and growing 15% annually.
âFor Bactiguard this is a milestone. India is one of the worldâs most interesting and fastest growing markets right now, and we are proud to be able to help India with our expertise in the field of infection protection. We are hoping to reduce the number of hospital acquired infections and thereby also reduce the use of antibiotics in India together with Cadila. I am very proud to be able to work with Cadila to improve health care in Indiaâ, says Christian Kinch, CEO of Bactiguard.
This co-operation between Cadila Pharmaceuticals and Bactiguard was facilitated by Dr C.B. Sanjeevi of Karolinska Institute and Invest Sweden assisted together. Another important role was played by the Swedish EKN, Export Credit Guarantee Authority to make the exclusive agreement.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last six decades, it has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over 90 other countries across the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals.